EAM Investors’s Juno Therapeutics, Inc. JUNO Stock Holding History

EAM Investors’s Portfolio JUNO Stock Details JUNO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q2	–	Sell	-56,704	Closed	-$3.44M	–	419
2015 Q1	$3.44M	Buy	+56,704	New	+$2.75M	0.4%	96

Other funds holding JUNO

Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

EAM Investors's JUNO Position: Q2 2015 in Review

EAM Investors sold out of Juno Therapeutics, Inc. (JUNO) in Q2 2015, closing a stake of 56,704 shares — an estimated $3.44M sold.

EAM Investors first reported a position in JUNO in Q1 2015 and held it in 1 quarter. The position peaked at $3.44M in Q1 2015. 154 funds tracked by Wall St. Rank hold JUNO as of Q2 2015.

EAM Investors reported no remaining Juno Therapeutics, Inc. position as of Q2 2015 after selling out during the quarter.
EAM Investors sold 56,704 Juno Therapeutics, Inc. shares in Q2 2015, an estimated $3.44M.
EAM Investors first reported a position in Juno Therapeutics, Inc. in Q1 2015 and held it in 1 quarter.
EAM Investors's Juno Therapeutics, Inc. position peaked at $3.44M in Q1 2015.
154 funds tracked by Wall St. Rank held Juno Therapeutics, Inc. as of Q2 2015.

Based on EAM Investors's 13F filing for Q2 2015, filed 13 Aug 2015.